Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively

Fig. 1

Current relevant therapies in the treatment of patients with CLL that are discussed in this review and main molecular targets. Ab, antibody; BCL-2, B-cell lymphoma 2; BTK, Bruton’s Tyrosine kinase; CAR-T, chimeric antigen receptor T; Fc, fragment crystallizable region; PI3K, phosphoinositide 3-kinase; ROR1, Receptor Tyrosine Kinase Like Orphan Receptor 1; scFv, single-chain variable fragment

Back to article page